Q-omics provides the consensus-scored IL2RA profile across patient tissues and cancer cell-line models. IL2RA expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, IL2RA is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, IL2RA RNA expression shows 23,702 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, HNSC, and GBM as cancer lineages where IL2RA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL2RA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL2RA survival associations across molecular data types. IL2RA RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL2RA RNA expression–survival associations across cancer types. High IL2RA expression shows unfavorable associations in KIRP, LAML and LUSC, but favorable associations in SKCM, HNSC and CESC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for IL2RA RNA expression.
This table summarizes IL2RA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for IL2RA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL2RA shows higher tumor expression in HNSC, KIRC, LUAD, STAD, BRCA and LUSC. The HNSC box plot shows higher IL2RA RNA expression in tumor versus normal tissue (log2 FC = +1.494, t-test p < 0.001).
This table shows molecular features associated with IL2RA in patient tissues and cancer cell lines. In patient samples, IL2RA shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, IL2RA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and PANCREAS.
